Skip to main content
. 2020 May 5;11:2206. doi: 10.1038/s41467-020-16067-1

Fig. 5. Drug–target network analysis in children, adolescents, and young adults (C-AYA) with solid tumors.

Fig. 5

Known cancer-predisposing genes (KCPG) and candidate genes with germline pathogenic/likely pathogenic (P/LP) variants in C-AYA patients with solid tumors that have existing FDA-approved antineoplastic and immunomodulating-related compounds, in regard to their affected tumor types. ACT adrenocortical carcinoma, CNS central nervous system, EWS Ewing sarcoma, GCT germ cell tumor, HGG high-grade glioma, LGG low-grade glioma, NBL neuroblastoma, NM non-malignant tumor, OS osteosarcoma, OST other solid tumors, PGL paraganglioma, RB retinoblastoma, RHB rhabdomyosarcoma, STS soft tissue sarcoma, WLM Wilms tumor.